Evidence map›Paper›PMID 40699494›Full record

ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025

Angiotensin-converting enzyme genotypes and sarcoidosis: Correlation with susceptibility, progression and treatment response.

Janne Møller, Ole Hilberg, Peter Henrik Nissen, Holger Jon Møller, Karen Elisabeth Bendstrup

Abstract read
In one paragraph

Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Janne MøllerAarhus University Hospital, Aarhus, Denmark.ORCID 0000-0003-1839-3669
Ole HilbergSygehus Lillebaelt Hospital, Vejle, Denmark. University of Southern Denmark.ORCID 0000-0002-3075-3463
Peter Henrik NissenAarhus University Hospital, Aarhus, Denmark. Aarhus University, Aarhus, Denmark.ORCID 0000-0002-8201-1306
Holger Jon MøllerAarhus University Hospital, Aarhus, Denmark. Aarhus University, Aarhus, Denmark.ORCID 0000-0001-7687-5995
Karen Elisabeth BendstrupAarhus University Hospital, Aarhus, Denmark. Aarhus University, Aarhus, Denmark.ORCID 0000-0002-4238-6963

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPrevious research has yielded conflicting results regarding the association between ACE genotypes and both susceptibility to sarcoidosis and disease prognosis. While some studies have found no significant impact of the ACE genotype on sarcoidosis susceptibility, others have suggested that the DD genotype may be associated with an increased risk of developing the disease and a poor prognosis. This study aimed to evaluate the influence of ACE genotypes on the susceptibility to sarcoidosis, prognosis and treatment response in patients with pulmonary sarcoidosis in Denmark.

methodsPatients with sarcoidosis were consecutively enrolled and genotyped using allele-specific PCR and high-resolution melting methods. The distribution of ACE genotypes was then compared with that of 400 healthy Danish individuals. To assess the impact of ACE genotypes on sarcoidosis prognosis, their association with changes in pulmonary function tests, radiological staging over 24 months, the frequency of Löfgren's syndrome, and treatment response were analyzed.

resultsAmong 148 patients with sarcoidosis, the frequency of the II, ID, and DD genotypes was 25%, 52%, and 23%, respectively. No significant difference was observed in the distribution of ACE genotypes between patients and controls. Prognostic factors and treatment response also did not vary among the genotypes.  Conclusion: Our findings do not support an association between the ACE I/D genotypes and sarcoidosis susceptibility, prognosis or response to treatment in a Danish cohort.

Identifiers

PMID40699494
PMCPMC12242871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.